✦ LIBER ✦

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

✍ Scribed by DeAngelo, D J; Spencer, A; Bhalla, K N; Prince, H M; Fischer, T; Kindler, T; Giles, F J; Scott, J W; Parker, K; Liu, A; Woo, M; Atadja, P; Mishra, K K; Ottmann, O G

Book ID: 121699786
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 593 KB
Volume: 27
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2013.38

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

605 A Phase 1, Open-label, Dose-escalati

605 A Phase 1, Open-label, Dose-escalation Study of Oral Administration of the Investigational Agent MLN0128 in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid Malignancies

✍ Burris, H.; Hart, L.; Kurkjian, C.; Berk, G.; Lipman, P.; Patel, C.; Rommel, C.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

A phase I, open label, dose-escalating s

A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2

✍ F. Cardoso; Azambuja; C. Bernard; L. Dirix; D. De Becker; S. Bartholomeus; V.D H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Phase Ib/II, open-label, dose-escalation

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

✍ Kefford, Richard; Sullivan, Ryan J; Miller, Wilson H; Elez, Elena M; Tan, Daniel 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 91 KB